Mapk-activated protein kinase 2 contributes to clostridium difficile-associated inflammation

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 713-722

  Bobo, Linda D ^a   El Feghaly, Rana E ^a   Chen, Yee Shiuan ^a   Dubberke, Erik R ^a   Han, Zhuolin ^a   Baker, Alexandra H ^a   Li, Jinmei ^a   Burnham, Carey Ann D ^a   Haslam, David B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOSKELETON; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; CRICETINAE; CYTOKINES; FECES; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RAC1 GTP-BINDING PROTEIN;

EID: 84874693787     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00186-12     Document Type: Article

References (71)

1. Archibald LK, Banerjee SN, Jarvis WR. 2004. Secular trends in hospitalacquired Clostridium difficile disease in the United States, 1987-2001. J. Infect. Dis. 189:1585-1589.
2. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
3. Musher DM, Logan N, Mehendiratta V. 2006. Epidemic Clostridium difficile. N. Engl. J. Med. 354:1199-1203.
4. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. 2007. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin. Infect. Dis. 45:1543-1549.
5. Dubberke ER, Gerding DN, Classen D, Arias KM, Podgorny K, Anderson DJ, Burstin H, Calfee DP, Coffin SE, Fraser V, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Mermel LA, Nicolle L, Pegues DA, Perl TM, Saint S, Salgado CD, Weinstein RA, Wise R, Yokoe DS. 2008. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect. Control Hosp. Epidemiol. 29(Suppl. 1):S81-S92.
6. Reinert DJ, Jank T, Aktories K, Schulz GE. 2005. Structural basis for the function of Clostridium difficile toxin B. J. Mol. Biol. 351:973-981.
7. Ishida Y, Maegawa T, Kondo T, Kimura A, Iwakura Y, Nakamura S, Mukaida N. 2004. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J. Immunol. 172:3018-3025.
8. Hippenstiel S, Soeth S, Kellas B, Fuhrmann O, Seybold J, Krull M, Eichel-Streiber C, Goebeler M, Ludwig S, Suttorp N. 2000. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood 95:3044-3051.
9. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719-722.
10. Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M. 2006. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101:1112-1116.
11. Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M, DuPont HL. 2007. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin. Gastroenterol. Hepatol. 5:964-968.
12. Castagliuolo I, Karalis K, Valenick L, Pasha A, Nikulasson S, Wlk M, Pothoulakis C. 2001. Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280:G539-G545.
13. de Araujo Junqueira AF, Dias AA, Vale ML, Spilborghs GM, Bossa AS, Lima BB, Carvalho AF, Guerrant RL, Ribeiro RA, Brito GA. 2011. Adenosine deaminase inhibition prevents Clostridium difficile toxin Ainduced enteritis in mice. Infect. Immun. 79:653-662.
14. Ng J, Hirota SA, Gross O, Li Y, Ulke-Lemee A, Potentier MS, Schenck LP, Vilaysane A, Seamone ME, Feng H, Armstrong GD, Tschopp J, Macdonald JA, Muruve DA, Beck PL. 2010. Clostridium difficile toxininduced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139:542-552.
15. Jarchum I, Liu M, Lipuma L, Pamer EG. 2011. Toll-like receptor-5 stimulation protects mice from acute Clostridium difficile colitis. Infect. Immun. 80:2989-2996.
16. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JK, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Investig. 105:1147-1156.
17. Lee JY, Park HR, Oh YK, Kim YJ, Youn J, Han JS, Kim JM. 2007. Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A. J. Mol. Med. 85: 1393-1404.
18. Tixier E, Lalanne F, Just I, Galmiche JP, Neunlist M. 2005. Human mucosa/submucosa interactions during intestinal inflammation: involvement of the enteric nervous system in interleukin-8 secretion. Cell Microbiol. 7:1798-1810.
19. Gaestel M, Mengel A, Bothe U, Asadullah K. 2007. Protein kinases as small molecule inhibitor targets in inflammation. Curr. Med. Chem. 14: 2214-2234.
20. Cargnello M, Roux PP. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75:50-83.
21. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, Lamont JT. 2005. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 129:1875-1888.
22. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, LaMont JT. 2005. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J. Biol. Chem. 280: 21237-21245.
23. Su X, Ao L, Zou N, Song Y, Yang X, Cai GY, Fullerton DA, Meng X. 2008. Post-transcriptional regulation of TNF-induced expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells: an obligatory role for the p38 MAPK-MK2 pathway dissociated with HSP27. Biochim. Biophys. Acta 1783:1623-1631.
24. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18:4969-4980.
25. Funding AT, Johansen C, Gaestel M, Bibby BM, Lilleholt LL, Kragballe K, Iversen L. 2009. Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J. Investig. Dermatol. 129:891-898.
26. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez JB. 2007. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 27:170-181.
27. Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H, Shen X. 2006. MAPKactivated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27. J. Biol. Chem. 281:37215-37226.
28. Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M. 2002. Distinct cellular functions of MK2. Mol. Cell. Biol. 22:4827-4835.
29. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD. 2009. Benzothiophene inhibitors of MK2 Part 2: improvements in kinase selectivity and cell potency. Bioorg. Med. Chem. Lett. 19:4882-4884.
30. Nayana RS, Bommisetty SK, Singh K, Bairy SK, Nunna S, Pramod A, Muttineni R. 2009. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies. J. Chem. Infect. Model. 49:53-67.
31. Xiong Z, Gao DA, Cogan DA, Goldberg DR, Hao MH, Moss N, Pack E, Pargellis C, Skow D, Trieselmann T, Werneburg B, White A. 2008. Synthesis and SAR studies of indole-based MK2 inhibitors. Bioorg. Med. Chem. Lett. 18:1994-1999.
32. Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, Moebitz H, Revesz L, Scheufler C, Velcicky J, Waelchli R, Huppertz C. 2008. Pyrrolopyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Bioorg. Med. Chem. Lett. 18:6142-6146.
33. Keminer O, Kraemer J, Kahmann J, Sternberger I, Scheich C, Jungmann J, Schaert S, Winkler D, Ichihara O, Whittaker M, Ullmann D, Hesterkamp T. 2009. Novel MK2 inhibitors by fragment screening. Comb. Chem. High Throughput Screen. 12:697-703.
34. Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P. 2008. MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin. Ther. Targets 12:921-936.
35. Pruitt RN, Chagot B, Cover M, Chazin WJ, Spiller B, Lacy DB. 2009. Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J. Biol. Chem. 284:21934-21940.
36. Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. 2007. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J. Med. Chem. 50:2647-2654.
37. Bliss DZ, Johnson S, Clabots CR, Savik K, Gerding DN. 1997. Comparison of cycloserine-cefoxitin-fructose agar (CCFA) and taurocholate-CCFA for recovery of Clostridium difficile during surveillance of hospitalized patients. Diagn. Microbiol. Infect. Dis. 29:1-4.
38. Sambol SP, Tang JK, Merrigan MM, Johnson S, Gerding DN. 2001. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J. Infect. Dis. 183:1760-1766.
39. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992.
40. Bruno MCE, Kaetzel CS. 2005. Long-term exposure of the HT-29 human intestinal epithelial cell line to TNF causes sustained up-regulation of the polymeric Ig receptor and proinflammatory genes through transcriptional and posttranscriptional methods. J. Immunol. 174:7278-7284.
41. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
42. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263.
43. Walchli S, Skanland SS, Gregers TF, Lauvrak SU, Torgersen ML, Ying M, Kuroda S, Maturana A, Sandvig K. 2008. The mitogen-activated protein kinase p38 links Shiga toxin-dependent signaling and trafficking. Mol. Biol. Cell 19:95-104.
44. Schieven GL. 2009. The p38alpha kinase plays a central role in inflammation. Curr. Top. Med. Chem. 9:1038-1048.
45. Shiryaev A, Moens U. 2010. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a trois or menage a quatre? Cell Signal. 22:1185-1192.
46. Saenz JB, Li J, Haslam DB. 2010. The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response. Cell Microbiol. 12:516-529.
47. Ryden EB, Lipman NS, Taylor NS, Rose R, Fox JG. 1991. Clostridium difficile typhlitis associated with cecal mucosal hyperplasia in Syrian hamsters. Lab. Anim. Sci. 41:553-558.
48. Chang J, Rohwer RG. 1991. Clostridium difficile infection in adult hamsters. Lab. Anim. Sci. 41:548-552.
49. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillinresistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 32:387-390.
50. Savidge T. 2003. Toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420.
51. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat. Rev. Gastroenterol. Hepatol. 8:17-26.
52. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
53. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. 1978. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet ii:226-228.
54. Pepin J. 2008. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin. Infect. Dis. 46:1493-1498.
55. Bartlett JG, Tedesco FJ, Shull S, Lowe B, Chang T. 1980. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 78:431-434.
56. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, Group OPTCS. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
57. McFarland LV. 2005. Alternative treatments for Clostridium difficile disease: what really works? J. Med. Microbiol. 54:101-111.
58. Vaishnavi C, Thapa BR, Thennarasu K, Singh K. 2002. Faecal lactoferrin assay as an adjunct to Clostridium difficile diarrhoea. Indian J. Pathol. Microbiol. 45:69-73.
59. Vaishnavi C, Bhasin D, Kochhar R, Singh K. 2000. Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes Infect. 2:1827-1830.
60. Miller JR, Barrett LJ, Kotloff K, Guerrant RL. 1994. A rapid test for infectious and inflammatory enteritis. Arch. Intern. Med. 154:2660-2664.
61. Gerhard R, Tatge H, Genth H, Thum T, Borlak J, Fritz G, Just I. 2005. Clostridium difficile toxin A induces expression of the stress-induced early gene product RhoB. J. Biol. Chem. 280:1499-1505.
62. Cohen S, Fleischmann R. 2010. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr. Opin. Rheumatol. 22:330-335.
63. Ronkina N, Kotlyarov A, Gaestel M. 2008. MK2 and MK3-a pair of isoenzymes? Front. Biosci. 13:5511-5521.
64. Gaestel M. 2006. MAPKAP kinases-MKs-two's company, three's a crowd. Nat. Rev. Mol. Cell Biol. 7:120-130.
65. Jones SW, Brockbank SM, Clements KM, Le Good N, Campbell D, Read SJ, Needham MR, Newham P. 2009. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology. Osteoarthr. Cartilage 17:124-131.
66. Park JK, Ronkina N, Hoft A, Prohl C, Menne J, Gaestel M, Haller H, Meier M. 2008. Deletion of MK2 signalling in vivo inhibits small Hsp phosphorylation but not diabetic nephropathy. Nephrol. Dial. Transplant. 23:1844-1853.
67. Lee JY, Kim H, Cha MY, Park HG, Kim YJ, Kim IY, Kim JM. 2009. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway. J. Mol. Med. 87:169-180.
68. Bennett WE, Jr, Gonzalez-Rivera R, Shaikh N, Magrini V, Boykin M, Warner BB, Hamvas A, Tarr PI. 2009. A method for isolating and analyzing human mRNA from newborn stool. J. Immunol. Methods 349: 56-60.
69. Bennett WE, Jr, Gonzalez-Rivera R, Puente BN, Shaikh N, Stevens HJ, Mooney JC, Klein EJ, Denno DM, Draghi AII, Sylvester FA, Tarr PI. 2010. Proinflammatory fecal mRNA and childhood bacterial enteric infections. Gut Microbes 1:209-212.
70. Archbald-Pannone L, Sevilleja JE, Guerrant R. 2010. Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility. J. Am. Med. Directors Assoc. 11:263-267.
71. Rocha MF, Maia ME, Bezerra LR, Lyerly DM, Guerrant RL, Ribeiro RA, Lima AA. 1997. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect. Immun. 65:2740-2746.